雷帕鸣效果好不好

Sirolimus is an immunosuppressant that inhibits the activation and proliferation of T lymphocytes by inhibiting their response to stimulation by antigens and cytokines (IL-2, IL-4 and IL-15). For patients after kidney transplantation, rapamycin is an effective treatment option to prevent organ rejection.

Is India's Biocon Repa Ming effective?

Rapamin sirolimus combined with low-dose cyclosporine A is a better immunosuppressive treatment option after renal transplantation, and the use of rapamin sirolimus can reduce the dose of CNI. After renal transplantation, it is safe and effective to control the steady-state trough concentration of rapamycin sirolimus at 4-8ng/ml or 5-8ng/ml. Rapamin also reduces the incidence of non-melanoma skin cancer after kidney transplantation. In addition, rapamycin sirolimus has also achieved good anti-rejection effects after heart transplantation, lung transplantation, corneal transplantation and other transplants, but the therapeutic concentration has not been reported.

It can be seen that the use of sirolimus in kidney transplant patients can not only effectively reduce the risk of rejection, but is also relatively safe. However, immunosuppression may also increase the risk of infection, including activation of latent viral infections, fatal infections, and sepsis. Patients need to take relevant precautions, including preventive treatment of Pneumocystis jiroveci pneumonia (PCP) 1 year after transplantation, and prevention of cytomegalovirus (CMV) 3 months after transplantation.

It is understood that it has been launched in China, and patients can purchase it at major domestic hospitals or pharmacies with a prescription issued by a doctor. However, the price of its original drug is relatively high, so many patients choose India's Biocon Repamin. Biocon India, one of India's top three biotech companies, is an emerging global biopharmaceutical company that is committed to reducing the cost of treatment for chronic diseases such as diabetes, cancer and autoimmune diseases by leveraging India's cost advantages to provide affordable healthcare solutions to patients, partners and healthcare systems around the world.

Recommended related hot articles: /newsDetail/86898.html